Abstract
Poly(ADP-ribose) synthetase inhibitor, INO-1001, is known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage. Recent evidence has suggested that PARP inhibition may also be a way of selectively targeting p53 deficient cancer cells. The present study tested INO-1001 for its in vivo effect on the chemoresponse of two p53 deficient tumors, human breast cancer MDA-MB-231 and murine mammary carcinoma MCa-K. Doxorubicin was used as the DNA damaging agent and tumor growth delay assay was used as the endpoint. Results showed that INO-1001 was highly effective in enhancing the anti-tumor effects of Doxorubicin for both MDA-MB-231 (EF = 1.88) and MCa-K (EF = 1.64). We conclude that PARP inhibitor INO-1001 has high potential for enhancing the anti-tumor effects of chemotherapy agents such as Doxorubicin against p53 deficient breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1-5 |
Number of pages | 5 |
Journal | Investigational New Drugs |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2008 |
Keywords
- Doxorubicin
- Doxorubicin-induced apoptosis
- INO-1001
- Poly(ADP-ribose)
- p53-Deficient cancer cells
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)